Who Owns Pro Medicus Company?

Who owns Pro Medicus?

Pro Medicus, an Australian healthcare informatics company, has become a global leader in enterprise imaging solutions since its founding in 1983. Headquartered in Richmond, Australia, it specializes in providing advanced platforms for medical imaging, enhancing efficiency and diagnostic capabilities in radiology.

Understanding the ownership of Pro Medicus is key, especially given its significant market presence and impressive financial growth. As of July 30, 2025, its market capitalization reached A$33.40 billion, with a net profit of $51.7 million reported for the six months ending December 2024, marking a 42.7% increase.

The ownership of Pro Medicus is primarily distributed among institutional investors, the public, and its founders. As of July 2025, major institutional shareholders hold a substantial portion of the company's stock. These include investment management firms and superannuation funds that invest on behalf of a large number of individuals. The public float represents shares available for trading by individual investors on the stock exchange. Founders and early employees also retain significant stakes, often influencing the company's long-term strategy and governance.

Key institutional investors, such as those managing large diversified portfolios, play a crucial role in Pro Medicus's shareholder base. Their investment decisions can impact share price and corporate governance. The company's strong performance, including revenue growth of 31.1% to $97.2 million in the six months to December 2024, makes it an attractive proposition for these entities. The company's innovative approach, exemplified by its Pro Medicus BCG Matrix analysis, further solidifies its appeal to a broad range of investors.

Pro Medicus Limited was co-founded in 1983 by Dr. Sam Hupert and Anthony Hall, recognizing the significant potential of computers in medicine. Dr. Hupert, a medical graduate, transitioned to full-time management of the company in late 1984. Anthony Hall has been instrumental in developing the group's core software systems.

Founding Visionaries

Dr. Sam Hupert and Anthony Hall are the co-founders of Pro Medicus. Their shared interest in Burgundy wine led to their initial meeting and the subsequent establishment of the company.

Early Ownership Structure

At the company's inception, Dr. Hupert and Hall were the primary owners. Their foundational role in the company's establishment is reflected in their continued significant shareholdings.

Co-Founders' Shareholding

As of December 4, 2024, Dr. Sam Hupert and Anthony Hall remain the two largest shareholders. Each holds over 24 million shares, collectively representing 46% of the total outstanding shares.

Insider Ownership Significance

The substantial insider ownership by the co-founders indicates a strong vested interest in the company's long-term success and strategic direction.

Foundational Control

The founders' enduring and significant holdings underscore their foundational control and commitment to the company's vision since its inception in 1983.

Early Investment Details

Specific details regarding early equity splits or initial backing from angel investors or friends and family are not publicly detailed in available information.

The early ownership of Pro Medicus was firmly rooted with its co-founders, Dr. Sam Hupert and Anthony Hall. Their substantial and ongoing shareholdings, with each holding over 24 million shares as of December 4, 2024, collectively accounting for 46% of the company's total outstanding shares, highlight their deep commitment and foundational control. This significant insider ownership suggests a strong alignment of interests between the founders and the company's performance, a key factor in understanding Pro Medicus ownership. Their initial meeting over a shared passion for wine ultimately led to the creation of a company that has significantly impacted the medical technology landscape, a journey that can be further explored in articles like Marketing Strategy of Pro Medicus.

Pro Medicus Ownership Snapshot

The ownership structure of Pro Medicus is significantly influenced by its co-founders, Dr. Sam Hupert and Anthony Hall, who remain the largest shareholders. This concentrated ownership by the founders is a defining characteristic of the company's early and ongoing governance.

• Co-founded in 1983 by Dr. Sam Hupert and Anthony Hall.
• Dr. Hupert transitioned to full-time management in late 1984.
• Anthony Hall is the principal architect of the core software systems.
• As of December 4, 2024, both founders hold over 24 million shares each.
• Their combined stake represents 46% of Pro Medicus's total outstanding shares.
• This substantial insider ownership indicates strong founder commitment.

Complete Pro Medicus Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

Pro Medicus Limited's journey began with its listing on the Australian Securities Exchange (ASX) on October 10, 2000. Since its initial public offering, the company has experienced significant market capitalization growth, expanding from A$142.00 million to A$33.40 billion by July 30, 2025, reflecting a compound annual growth rate of 24.61%.

The ownership structure of Pro Medicus shows a strong presence of its founders, with individual insiders holding a substantial 49% stake as of July 19, 2025. CEO Sam Hupert and co-founder Anthony Hall are the largest shareholders, each possessing 23% of the common stock. Their combined 46% ownership as of December 4, 2024, underscores their continued significant influence on the company's direction. Institutional investors, including The Vanguard Group, Inc., BlackRock, Inc., and Dimensional Fund Advisors LP, collectively own 14% of the company's stock, indicating growing interest from the financial sector. The general public accounts for the remaining 37% of Pro Medicus stock ownership, demonstrating broad investor appeal.

Pro Medicus Ownership Snapshot

Pro Medicus's ownership is characterized by significant founder influence and increasing institutional backing. This blend suggests a stable yet growing investor base.

• Individual insiders hold 49% of Pro Medicus shares.
• CEO Sam Hupert is the largest individual shareholder with 23%.
• Institutional investors represent 14% of Pro Medicus company structure.
• The general public holds 37% of the company's stock.
• The company's market capitalization reached A$33.40 billion by July 30, 2025.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

The board of directors for Pro Medicus Limited includes its co-founders, Dr. Sam Hupert and Anthony Hall, who also hold executive roles. Peter Terence Kempen chairs the board, with Alice Williams serving as a Non-Executive Director. As of June 30, 2024, Anthony Glenning, Dr. Leigh Farrell, Ms. Deena Shiff, and Ms. Alice Williams were identified as independent directors.

The significant shareholdings of the co-founders, who collectively owned 46% of the company's outstanding shares as of December 4, 2024, indicate a strong alignment between management and ownership, granting them considerable influence over company decisions. The company's corporate governance framework, detailed in its annual reports, adheres to the ASX Corporate Governance Principles & Recommendations, and there is no public record of recent proxy battles or activist investor campaigns impacting its structure.

Pro Medicus Ownership and Board Influence

Pro Medicus Limited's ownership structure is heavily influenced by its co-founders, who are also key executives. This insider ownership, representing 46% of shares as of December 4, 2024, provides substantial voting power and strategic direction. Understanding this dynamic is crucial for assessing Pro Medicus company structure and Pro Medicus investor relations.

• Co-founders hold executive and board positions.
• Significant insider ownership grants considerable voting power.
• The board includes both executive and independent directors.
• Corporate governance aligns with ASX principles.
• This ownership model impacts the Revenue Streams & Business Model of Pro Medicus.

Pro Medicus Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

Recent developments have significantly shaped Pro Medicus's ownership landscape. The company initiated an equity buyback program in March 2025, aiming to repurchase up to 10% of its issued shares by March 2026. This move, alongside substantial contract wins and strong financial performance, influences investor interest and the overall Pro Medicus ownership structure.

The company's financial performance has been a key driver of investor interest, with a significant increase in net profit and revenue for the half-year ended December 31, 2024. This robust growth, particularly in the North American market, coupled with substantial contract wins and renewals, solidifies its market position. Pro Medicus's strategic investments in new opportunities and AI further signal its commitment to future growth, making it an attractive prospect for a diverse range of Pro Medicus shareholders.

Co-founder Holdings and Sales

Pro Medicus co-founders Sam Hupert and Anthony Hall remain the largest Pro Medicus shareholders. In December 2024, they sold a combined two million shares for $513.5 million, a transaction that represented a minor portion of their overall holdings.

Equity Buyback Initiative

The company announced an equity buyback program on March 31, 2025, allowing for the repurchase of up to 10% of its issued share capital. This program is designed to enhance shareholder value and reflects confidence in the company's financial outlook.

Financial Performance and Growth Drivers

Pro Medicus reported a 42.7% increase in net profit to $51.7 million for the half-year ended December 31, 2024. Revenue from ordinary activities grew by 31.1% to $97.2 million, with North America showing a 34.6% revenue increase to $86.4 million.

Strategic Contract Wins and Renewals

Significant contract wins, including a minimum of $365 million over 7-10 years with major healthcare providers, alongside contract renewals, underscore the company's expanding market reach. These agreements are crucial for understanding the Pro Medicus company structure and its future revenue streams.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE